Exact Sciences Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Exact Sciences Bundle
Actionable Strategy Starts Here
Curious where Exact Sciences’ products land—Stars, Cash Cows, Dogs, or Question Marks? This snapshot hints at the story, but the full BCG Matrix lays it out quadrant by quadrant with crisp data and strategic moves you can act on. Buy the complete report for a Word narrative plus an editable Excel summary, clear recommendations, and a ready-to-use roadmap for where to invest, divest, or double-down. Get instant access and skip the guesswork.
Stars
Cologuard (stool DNA CRC screening)
Cologuard is Exact Sciences' flagship, category-defining stool-DNA CRC screen, generating roughly $1.6B of company revenue in 2023 and processing just over 1M tests annually into 2023–24; it continues to pull share from colonoscopy and FIT as CRC screening prevalence rises and primary care adoption grows. Heavy promotion and payer contracting remain important, but the commercialization flywheel is expanding the eligible screening pool—keep investing to cement leadership.
Oncotype DX Breast Recurrence Score
Oncotype DX is the guideline-backed gold standard for early breast cancer decision support, listed in NCCN and ASCO guidelines and used in over 1 million patients globally. High clinical utility and entrenched oncologist behavior sustain steady demand and industry-leading margins, making it a cash-generating Stars asset. It requires periodic data refreshes and ongoing KOL engagement to defend the moat and fund next-wave R&D.
Brand trust + guideline inclusion
Exact’s credibility with major societies and payers accelerates adoption across launches, helping drive company revenue above $3 billion in 2024 and expanding Cologuard use to over 10 million screened patients to date. That stamp of approval converts slower-moving systems and large IDNs, shortening sales cycles and boosting lifetime value. It’s not a SKU, but it behaves like one: a reusable asset that compounds with each guideline or payer win. Keep investing in evidence and outcomes stories to sustain this multiplier effect.
Integrated screening experience (ordering, reminders, logistics)
Integrated screening experience (ordering, reminders, logistics) drives higher completion and market share; patient navigation and PCP workflow integration can boost screening completion by up to 20 percentage points per program evaluations. Operational ease is a competitive weapon that increases adherence and retention. Scale lowers per-test costs and deepens health-system stickiness. Keep tightening the loop from script to result.
- Navigation raises completion up to 20pp
- Operational ease = competitive moat
- Scale reduces unit cost, increases stickiness
- Tighten script-to-result loop
Data moat and real‑world evidence engine
Massive volumes—over 2 million Cologuard tests annually in recent years—feed longitudinal real‑world evidence and iterative product tweaks, translating into stronger performance claims that shorten sales cycles and improve payer renewal rates. Competitors can replicate features but not the depth of longitudinal outcomes supporting clinical utility; relentless publishing (over 100 peer‑reviewed studies to date) widens the gap.
- Data scale: 2M+ tests/year
- Evidence depth: 100+ peer‑reviewed studies
- Commercial impact: faster sales cycles, stronger payer renewals
Two diagnostic leaders: billions in revenue, scale, evidence and payer momentum
Cologuard and Oncotype DX are Stars: Cologuard ≈$1.6B revenue (2023) with ~2M tests/year and Exact Sciences revenue >$3B (2024). Oncotype DX serves 1M+ patients globally and delivers high margins. Scale, 100+ studies and payer/guideline wins sustain growth; continue investing in evidence, navigation, and KOL engagement.
| Metric | Value |
|---|---|
| Cologuard rev (2023) | $1.6B |
| Tests/yr | ~2M |
| Company rev (2024) | $3B+ |
| Oncotype pts | 1M+ |
What is included in the product
Detailed Word Document
BCG Matrix of Exact Sciences: evaluates products as Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page Exact Sciences BCG Matrix: clear quadrant mapping to ease portfolio decisions and C-level reviews.
Cash Cows
Oncotype DX Breast (mature geographies)
In the U.S. and select EU markets Oncotype DX holds a dominant commercial position with high market share and modest growth as clinical use is routine in HR+/HER2- early breast cancer and supported by ASCO/NCCN guideline recommendations and TAILORx evidence.
Reimbursement remains stable across payers, utilization patterns are predictable, and sales and lab operations have achieved efficient unit economics, making Oncotype a steady cash generator for Exact Sciences that requires maintenance rather than blitz scaling.
Management focus should be on milking cash flows while defending guideline language and payer coverage to preserve long-term revenue durability rather than pursuing aggressive expansion.
Oncotype DX Prostate
Oncotype DX Prostate is smaller than its breast counterpart but entrenched with urologists and tumor boards, addressing decision-making in a market with roughly 288,300 new US prostate cancer cases annually (2024 ACS estimate). The market is mature, driving incremental uptake rather than step-change volume. Solid margins come from scale, lab efficiency and cross-sell within Exact Sciences’ portfolio. Maintain tight coverage and deploy reps where conversion is highest to protect ROI.
Oncotype DX Colon
Oncotype DX Colon occupies a niche but steady role in adjuvant therapy decisions for stage II/III colon cancer, with reliable reimbursement in eligible US patients as of 2024. It is not a growth rocket but generates recurring margin-supporting cash, enabling Exact Sciences to report 2024 total revenue of $4.16 billion while leveraging legacy oncology offerings. Low incremental investment is required to sustain clinical operations and lab capacity. Harvest cash and bundle the test within oncology contracting to improve deal economics.
Established payor contracts and IDN relationships
Established payor contracts and IDN relationships convert contracted lives into recurring, low-friction Cologuard volume; administrative load is predictable and appeal rates remain manageable, creating steady cash generation with limited upside. Maintain SLAs and pricing discipline to preserve margins and cash flow predictability.
- Recurring volume: predictable contracted lives
- Operational: known admin load, manageable appeals
- Strategy: enforce SLAs and pricing discipline
PreventionGenetics germline testing (select panels)
PreventionGenetics germline testing (select panels) sits as a cash cow for Exact Sciences: it leverages existing client relationships and lab scale to deliver steady low-single-digit revenue growth in 2024 while facing a mature, competitive market that limits upside. High lab throughput and panel bundling sustain gross margins above routine diagnostic averages, prompting menu optimization and retirement of low-margin SKUs to preserve profitability.
- Operational leverage with existing client base
- Mature market → tame growth (low single-digit, 2024)
- Throughput + bundling → improved margins
- Action: optimize menus, retire low-margin SKUs
Oncotype DX, Cologuard and PreventionGenetics: cash-generating tests underpin $4.16B revenue
Oncotype DX breast and Cologuard function as Exact Sciences cash cows, delivering predictable margins and supporting corporate cash flow amid 2024 total revenue of 4.16 billion. Oncotype Prostate is entrenched with urologists in a US market of ~288,300 annual cases (2024 ACS). PreventionGenetics panels show low-single-digit growth in 2024 with above-average lab margins.
| Product | Role | 2024 metric | Growth |
|---|---|---|---|
| Oncotype DX Breast | Primary cash generator | Supports corporate cash flow (part of $4.16B) | Modest |
| Oncotype DX Prostate | Entrenched | Market ~288,300 cases | Incremental |
| Cologuard | Recurring volume | Contracted lives, predictable | Stable |
| PreventionGenetics | Margin-supporting | Low-single-digit growth (2024) | Low |
Delivered as Shown
Exact Sciences BCG Matrix
The file you're previewing for Exact Sciences is the exact BCG Matrix report you’ll receive after purchase. No watermarks, no placeholders—just the fully formatted, analysis-ready document. It’s crafted for clarity and immediate use in strategy or presentations. Buy once, download instantly, edit or print as needed.
Dogs
Legacy assays without strong guideline backing
Legacy assays show low adoption and high education costs, representing a low single-digit revenue share in 2024 and creating persistent payer friction that ties up commercial and lab resources without moving the needle. Turnaround improvements rarely pay back in diagnostics absent a comprehensive data overhaul and real-world evidence build. Prune these assays or seek partnership exits to redeploy capital to higher-growth offerings.
Underperforming international beachheads
Markets where reimbursement lags and logistics drag down unit economics have left Exact Sciences with international beachheads that generate low single-digit percent of revenue in 2024; share stays low as local competitors undercut pricing. Cash trickles out, not in, pressuring margins and operating cash flow. Consider retreat, licensing, or distributor models to stem losses and reallocate capital to core US diagnostics.
One-off hospital lab collaborations with weak volume
One-off hospital lab collaborations that sounded strategic but never scaled delivered low incremental volumes, often <5% of partner lab throughput and under 2% of Exact Sciences total test volume in 2024, leaving service intensity high and margins thin. Goodwill from these deals is not expensed on the P&L, masking sunk costs. Sunset nonperforming collaborations and reallocate field support to scalable channels.
COVID-era testing tail
COVID-era testing tail: residual contracts and capabilities are no longer strategic for Exact Sciences; volumes collapsed over 90% from the 2021 peak by 2024, distracting core oncology teams and compressing margins, so exiting is preferable to maintaining zombie lines.
- Close, sell, or repurpose assets
- Exit cleanly to stop resource drain
- Redirect teams to high-growth oncology diagnostics
Overlapping panels with internal cannibalization
Overlapping panels chasing the same indication cannibalize volumes and lower per-SKU attach rates, hurting reimbursement positioning; Exact Sciences reported approximately $2.79 billion revenue in fiscal 2024, driven largely by screening products, so internal competition weakens core cash flow. Simplifying the catalog will reduce clinician confusion and clarify payer narratives, lifting attach and reimbursement—rationalize fast.
- Reduce SKU overlap to restore attach and pricing
- Clarify clinician messaging to prevent test substitution
- Align portfolio to highest-margin indications
Prune Dogs, fund core oncology: COVID volumes down >90%
Legacy assays, international beachheads and small lab deals generated low single-digit revenue share in 2024 (Exact Sciences fiscal revenue $2.79B), COVID testing volumes collapsed >90% vs 2021, and hospital collaborations <2% of test volume; prune, exit, or license these Dogs to free capital for core oncology growth.
| Metric | 2024 |
|---|---|
| Total revenue | $2.79B |
| COVID volume decline | >90% |
| Hospital deal share | <2% |
Question Marks
Blood-based multi-cancer early detection (MCED)
Blood-based MCED is a classic Question Mark for Exact Sciences: massive upside, minimal share today and heavy cash burn funding trials and commercialization. If pivotal readouts land and payers cover, it can flip to a Star rapidly; if not, it becomes a long, expensive detour. Bet big only where real-world sensitivity/specificity clear hurdles — e.g., published Galleri data shows ~51.5% overall sensitivity and ~99.5% specificity.
Oncoguard Liver (HCC screening/monitoring)
Oncoguard Liver sits as a Question Mark: rising clinical need and awareness for HCC screening—global liver cancer caused ~830,000 deaths in 2020, with US incident cases ~42,000/year (2024 estimates)—but clinical adoption remains early. Reimbursement and hepatology referral pathways are still forming, slowing uptake. Strategy: win targeted centers, generate outcomes data and real-world evidence, then scale. If outcomes compound, it could breakout into a core growth driver.
Next‑gen Cologuard (performance upgrade)
Next‑gen Cologuard aims to lift on the pivotal test’s 92% CRC sensitivity and ~87% specificity to lower false positives and unlock broader guideline use; with about one‑third of eligible US adults unscreened, brand recognition should drive rapid conversion if per‑test economics remain favorable. Success requires clean clinical/real‑world data, scaled manufacturing and a seamless handoff to avoid volume disruptions.
Minimal residual disease (MRD) monitoring assays
Minimal residual disease (MRD) monitoring sits in a high-growth liquid biopsy segment—analysts estimate ~20%+ CAGR for MRD/liquid biopsy through the late 2020s—yet faces fierce competitors and payer scrutiny over demonstrated clinical utility.
Clinicians demand clear actionability (treatment change, escalation or de‑escalation), not mere detection; without proven utility and coverage Exact Sciences’ MRD effort will remain cash‑consumptive.
If Exact nails clinical utility, guideline inclusion and reimbursement, MRD could become a meaningful growth leg; currently development and commercialization consume more cash than they return.
- market CAGR ~20%+ (late 2020s)
- key requirement: demonstrated actionable impact on therapy decisions
- primary risks: payer pushback, entrenched competitors
- opportunity: guideline adoption → reimbursement → scalable revenue
International Cologuard and Oncotype expansion (Asia/LatAm)
International Cologuard and Oncotype expansion in Asia/LatAm targets markets with ~4.7 billion people in Asia and ~660 million in Latin America (2024), but access is complex; early wins are uneven and strongly policy-driven. Local evidence and tiered pricing have lifted share in select markets; with reimbursement secured, scale can be substantial, yet growth remains a grind until coverage is widespread.
- Big population: Asia 4.7B, LatAm 660M (2024)
- Access: fragmented public/private reimbursement
- Early wins: pilot wins policy-linked
- Path to scale: local evidence + pricing + reimbursement
Blood MCED: 51.5% sens, 99.5% spec - pivotal reads + coverage decide fate
Blood‑based MCED: high upside, low share; Galleri ~51.5% sensitivity, ~99.5% specificity; pivotal readouts + coverage needed to become a Star.
Oncoguard Liver: early adoption for HCC; global liver cancer ~830,000 deaths (2020), US ~42,000 cases (2024 est); reimbursement uncertain.
Next‑gen Cologuard: leverages 92% CRC sensitivity; one‑third US unscreened—scale potential if economics hold.
MRD: >20% market CAGR (late 2020s) but high cash burn and payer scrutiny.
| Asset | Status | Metric | Path |
|---|---|---|---|
| MCED | Question Mark | 51.5%/99.5% | pivotal+coverage |
| MRD | Question Mark | CAGR ~20%+ | utility+reimbursement |